← Every company
BioMarin Pharmaceutical Inc Patents
What BioMarin Pharmaceutical Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
BMRN on carbonthat →Filings on file
52
Granted
0
Still pending
52
Filed under
3 names
52 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| TREATMENT OF NEURONAL CEROID LIPOFUSCINOSIS 3 (CLN3) WITH TPP1Filed as BIOMARIN PHARMACEUTICAL INC.2026-02-27GUILLERMO SERATTI | pending |
| HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATUREC12Q 1/6897, A61P 19/08, A61K 38/2242, C12N 15/1065, C12N 15/86, C12N2740/15043, C12Q 1/6883, C12Q2600/156Filed as BIOMARIN PHARMACEUTICAL INC.2025-12-05Sergio Covarrubias | pending |
| SMALL MOLECULES TO TREAT ALPHA-1-ANTITRYPSIN (A1AT) DEFICIENCY IN SPECIFIC PATIENT POPULATIONSFiled as BIOMARIN PHARMACEUTICAL INC.2025-11-13BRITTA HANDYSIDE | pending |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CALCIPHYLAXISFiled as BIOMARIN PHARMACEUTICAL INC.2025-11-07KURT GUNTER | pending |
| METHODS OF USING PROKARYOTIC PHENYLALANINE AMMONIA-LYASEFiled as BIOMARIN PHARMACEUTICAL INC.2025-10-23CELESTE DECKER | pending |
| TREATMENT OF SHORT STATURE WITH CNP VARIANTSFiled as BIOMARIN PHARMACEUTICAL INC.2025-08-04DANIEL J. WENDT | pending |
| SMALL MOLECULES TO TREAT ALPHA-1-ANTITRYPSIN (A1AT) DEFICIENCY IN SPECIFIC PATIENT POPULATIONSFiled as BIOMARIN PHARMACEUTICAL INC.2025-06-06Britta HANDYSIDE | pending |
| ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN ASTROCYTES USING AUTOREGULATORS FOR THE ASSESSMENT AND/OR TREATMENT OF SLC6A1 DISORDERSFiled as BioMarin Pharmaceutical Inc.2025-03-24Bryan Gore | pending |
| Treatment of Neuronal Ceroid Lipofuscinosis 3 (CLN3) With TPP1Filed as BIOMARIN PHARMACEUTICAL INC.2025-02-27Guillermo Seratti | pending |
| C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA IN CHILDRENA61K 38/2242, A61K 9/0019, A61K 9/19, A61K 38/1709, A61K 47/10, A61K 47/12, A61K 47/183, A61P 19/08, A61K 47/20, A61K 47/26Filed as BIOMARIN PHARMACEUTICAL INC.2025-01-22Jonathan Day | pending |
| TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOFA61K 38/00, C07K 14/65, C12N 9/2402, A61P 43/00, A61P 3/00, A61K 38/47, C07K2319/06, C12Y 302/0105Filed as BioMarin Pharmaceutical Inc.2025-01-17Mika Aoyagi-Scharber | pending |
| TREATMENT OF SHORT STATURE WITH CNP VARIANTSFiled as BIOMARIN PHARMACEUTICAL INC.2025-01-16Daniel J. Wendt | pending |
| CONJUGATES OF PHENYLALANINE AMMONIA-LYASE AND POEGMA AND METHODS FOR THEIR USEA61K 47/60, A61P 3/00, A61K 9/0019, A61K 38/51, C12Y 403/01005Filed as BIOMARIN PHARMACEUTICAL INC.2024-11-15Debobrato DAS | pending |
| CONJUGATES OF PHENYLALANINE AMMONIA-LYASE AND POEGMA AND METHODS FOR THEIR USEFiled as BIOMARIN PHARMACEUTICAL INC.2024-11-15DEBOBRATO DAS | pending |
| SMALL MOLECULES TO TREAT ALPHA-1-ANTITRYPSIN (A1AT) DEFICIENCY IN SPECIFIC PATIENT POPULATIONSFiled as BIOMARIN PHARMACEUTICAL INC.2024-11-14Britta HANDYSIDE | pending |
| CNP VARIANTS, CONJUGATES AND FORMULATIONS THEREOFFiled as BIOMARIN PHARMACEUTICAL INC.2024-11-08GOLAM JAKARIA, MD | pending |
| METHODS OF USING PROKARYOTIC PHENYLALANINE AMMONIA-LYASEFiled as BIOMARIN PHARMACEUTICAL INC.2024-10-25Celeste Decker | pending |
| CNP Variants, Conjugates and Formulations ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-10-24Md Golam Jakaria | pending |
| TREATMENT OF OSTEOGENESIS IMPERFECTA WITH C-TYPE NATRIURETIC PEPTIDE AND ANALOGS THEREOFFiled as BIOMARIN PHARMACEUTICAL INC.2024-10-07DANIEL J. WENDT | pending |
| TREATMENT OF SHORT STATURE WITH CNP VARIANTSFiled as BIOMARIN PHARMACEUTICAL INC.2024-09-23Jonathan Day | pending |
| Treatment of Short Stature With CNP VariantsFiled as BIOMARIN PHARMACEUTICAL INC.2024-09-23Jonathan Day | pending |
| CNP Variants, Conjugates and Formulations ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-09-17Md Golam Jakaria | pending |
| DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS OF THEIR PREPARATION AND USEFiled as BIOMARIN PHARMACEUTICAL INC.2024-08-30SURESH KUMAR AGARWAL | pending |
| TREATMENT OF SHORT STATURE WITH CNP VARIANTSFiled as BIOMARIN PHARMACEUTICAL INC.2024-08-30Jonathan Day | pending |
| COMPOUNDS AND COMPOSITIONS OF HIGHLY STEREOCHEMICALLY PURE INHIBITORS OF Z-AT POLYMERIZATION AND METHODS OF MANUFACTURING THE SAMEFiled as BIOMARIN PHARMACEUTICAL INC.2024-08-30JOHN GEORGE BOWEN | pending |
| SOLID FORMS OF N-1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS OF THEIR PREPARATIONFiled as BIOMARIN PHARMACEUTICAL, INC.2024-08-30KIRAN PEDDURI | pending |
| CONJUGATES OF PHENYLALANINE AMMONIA-LYASE AND POEGMA AND METHODS FOR THEIR USEFiled as BIOMARIN PHARMACEUTICAL INC.2024-08-21Debobrato DAS | pending |
| TREATMENT OF SHORT STATURE WITH CNP VARIANTSFiled as BIOMARIN PHARMACEUTICAL INC.2024-08-02Jonathan Day | pending |
| Use of C-Type Natriuretic Peptide Variants to Treat Skeletal DysplasiaA61K 9/19, A61K 38/1709, A61K 38/22, A61K 38/2242, A61K 47/60, Y02A 50/30, A61P 19/08, A61K 9/0019, A61K 9/08, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/20, A61K 47/26Filed as BIOMARIN PHARMACEUTICAL INC.2024-07-26Sherry Bullens | pending |
| CONJUGATES OF PHENYLALANINE AMMONIA-LYASE AND POEGMA AND METHODS FOR THEIR USEFiled as BIOMARIN PHARMACEUTICAL INC.2024-07-12Debobrato DAS | pending |
| Treatment of Osteogenesis Imperfecta With C-Type Natriuretic Peptide and Analogs ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-07-01Daniel J. Wendt | pending |
| Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses ThereofFiled as BioMarin Pharmaceutical Inc.2024-06-28Mika Aoyagi-Scharber | pending |
| CNP Variants, Conjugates and Formulations ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-06-14Md Golam Jakaria | pending |
| HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATUREFiled as BIOMARIN PHARMACEUTICAL INC.2024-06-07SERGIO COVARRUBIAS | pending |
| CNP TherapyA61K 38/17, A61P 19/08, C07K 14/435, G01N 33/573, G01N 33/6893, G01N2800/52Filed as BIOMARIN PHARMACEUTICAL INC.2024-06-06Georges Jeha | pending |
| ANALYTICAL METHODS FOR ADENO-ASSOCIATED VIRUS VECTOR GENOMES AND USES THEREOFFiled as BIOMARIN PHARMACEUTICAL INC.2024-06-06MICHAEL XAVIER DOSS JESUDOSS | pending |
| ADENO-ASSOCIATED VIRUS CAPSID PROTEINSC07K 14/005, C12N 15/86, A61P 21/00, A61P 21/04, A61K 38/00, A61K 48/00, C07K 14/4707, C12N2750/14122, C12N2750/14143, C12N2750/14144, C12N2750/14152, C12N2799/025Filed as BIOMARIN PHARMACEUTICAL INC.2024-05-28Peter Cameron COLOSI | pending |
| CNP Variants, Conjugates and Formulations ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-05-24Md Golam Jakaria | pending |
| METHODS OF TREATING ANTI-AAV SEROPOSITIVE HEMOPHILIA PATIENTSFiled as BIOMARIN PHARMACEUTICAL INC.2024-05-15CHRISTIAN VETTERMANN | pending |
| STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTSA61K 48/005, A61K 48/0075, C12N 15/86, A61P 7/04, A61K 9/0019, A61K 38/37, A61K 38/44, A61K 38/4846, C07K 14/755, C12N 7/00, C12N 9/0071, C12N2750/14143, C12Y 114/16001, C12Y 304/21022Filed as BIOMARIN PHARMACEUTICAL INC.2024-05-13Stuart BUNTING | pending |
| DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDESFiled as BIOMARIN PHARMACEUTICAL INC.2024-05-03THOMAS AARON HARTL | pending |
| DYSTROPHIN EXON SKIPPING OLIGONUCLEOTIDESC12N 15/113, C12N2310/11, C12N2310/315, C12N2310/321, C12N2310/3231, C12N2310/3341, C12N2310/335, C12N2310/3525Filed as BioMarin Pharmaceutical Inc.2024-05-03Thomas Aaron Hartl | pending |
| COMPOSITIONS AND METHODS FOR TREATING STXBP1 DISORDERSFiled as BIOMARIN PHARMACEUTICAL INC.2024-04-23JAN HSI LUI | pending |
| TREATMENT OF HEREDITARY ANGIOEDEMA WITH AAV GENE THERAPY VECTORS AND THERAPEUTIC FORMULATIONSA61K 48/0058, A61P 7/10, A61K 9/0019, A61K 38/55, A61K 45/06, A61K 47/10, A61K 47/18, A61K 47/26, A61K 48/0075, A61K 48/0083, C12N 15/86, C12N2750/14143, C12N2750/14145, C12N2830/008, C12N2830/50Filed as BIOMARIN PHARMACEUTICAL INC.2024-04-01Peter COLOSI | pending |
| High Throughput Screen for Genetic Variants Associated with Short StatureFiled as BIOMARIN PHARMACEUTICAL INC.2024-03-12Sergio Covarrubias | pending |
| Treatment of Osteogenesis Imperfecta With C-Type Natriuretic Peptide and Analogs ThereofFiled as BIOMARIN PHARMACEUTICAL INC.2024-03-12Daniel J. Wendt | pending |
| AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYC07K 14/005, C12N 7/00, A61K 48/0041, A61K 48/0075, C12N 15/86, C12N2750/14122, C12N2750/14142, C12N2750/14143, C12N2750/14151Filed as BIOMARIN PHARMACEUTICAL INC.2024-03-01Peter COLOSI | pending |
| DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS OF THEIR PREPARATIONFiled as BIOMARIN PHARMACEUTICAL INC.2024-03-01Sunil BATTU | pending |
| AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYC12N 15/86, C07K 14/005, C12N2750/14122, C12N2750/14143, C12N2750/14152Filed as BIOMARIN PHARMACEUTICAL INC.2024-03-01Peter COLOSI | pending |
| AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYC07K 14/005, C12N 15/86, A61K 48/0041, A61K 48/0075, C12N 7/00, C12N2750/14122, C12N2750/14143, C12N2750/14145Filed as BIOMARIN PHARMACEUTICAL INC.2024-03-01Peter COLOSI | pending |
| DOSAGE FORMS OF N-(1-(2-CHLORO-3-FLUOROPHENYL)-1-HYDROXYPENTAN-2-YL)-7-FLUORO-2-OXOINDOLINE-4-CARBOXAMIDE AND METHODS OF THEIR PREPARATIONFiled as BIOMARIN PHARMACEUTICAL INC.2024-03-01Heather Ann WENZEL | pending |
| AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYC07K 14/005, C12N 15/86, A61K 48/005, A61K 48/0058, C12N2750/14122, C12N2750/14143Filed as BIOMARIN PHARMACEUTICAL INC.2024-03-01Peter COLOSI | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on BMRN
Company overviewEverything on BMRN in one place, with the price.SEC filingsWhat BMRN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BMRN's own officers and directors buy and sell.Executive payWhat BMRN awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in BMRN.Funds holding itWhich funds and ETFs hold BMRN, and how big a bet.LobbyingWhat BMRN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on BMRN's account, and who they worked for.